We give a new life and purpose for the old drug anagrelide in the targeted GIST therapy


Sartar Therapeutics develops a new therapeutic option for GIST patients based on drug reformulation and repositioning of anagrelide, the drug that has been used to treat thrombocytemia, a platelet number increasing blood disease. Anagrelide will be reformulated into a slow-release drug product. Reformulation will improve pharmacokinetic properties of the candidate product to make it more efficacious, better tolerated and more convenient to use in therapy than the old product.